Biojam España SL, resulting from the formalization of the Portuguese pharmaceutical company’s presence in this market, emerges as a significant milestone in its European expansion.
The signing of the deed solidifies the company’s strategic entry into the Spanish landscape, representing a decisive step for partnership consolidation and the establishment of a robust presence. After giving special attention to Acute Lymphoblastic Leukemia, Biojam outlines its focus on critical areas such as General Surgery and Organ Transplantation. This new approach reflects the ongoing quest for innovative solutions and advanced therapeutics, reinforcing the company’s commitment to the development of cutting-edge medical approaches.
Anticipating a new phase of releases, Biojam announces that new proposals and advances in the field of health will be available from January 2024. This announcement underscores the company’s commitment to contributing to the progress of medicine and the well-being of patients, promoting significant advances in the European pharmaceutical landscape.
Biojam, where innovation is our DNA.
______
Madrid, November 2023.
